Details of the Drug Combinations

General Information of This Drug (ID: DM4F29C)

Drug Name
Crizotinib   DM4F29C
Synonyms Xalkori (TN); novel ALK inhibitors
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1013 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
ABIRATERONE + Crizotinib DCA8MEO ABIRATERONE Astrocytoma (Cell Line: U251) [2]
ABIRATERONE + Crizotinib DCP5II9 ABIRATERONE Chronic myelogenous leukemia (Cell Line: K-562) [2]
ABIRATERONE + Crizotinib DC0LRHZ ABIRATERONE Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
ABIRATERONE + Crizotinib DCSPP88 ABIRATERONE Plasma cell myeloma (Cell Line: RPMI-8226) [2]
ABIRATERONE + Crizotinib DCM74TX ABIRATERONE Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
ABIRATERONE + Crizotinib DCKWJHP ABIRATERONE Invasive ductal carcinoma (Cell Line: BT-549) [3]
ABIRATERONE + Crizotinib DCY0J6K ABIRATERONE Invasive ductal carcinoma (Cell Line: HS 578T) [3]
ABIRATERONE + Crizotinib DCNVG75 ABIRATERONE Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
ABIRATERONE + Crizotinib DC67F7D ABIRATERONE Malignant melanoma (Cell Line: LOX IMVI) [4]
ABIRATERONE + Crizotinib DC7TM8Q ABIRATERONE Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Amonafide + Crizotinib DCERVDN Amonafide Adenocarcinoma (Cell Line: DU-145) [2]
Amonafide + Crizotinib DCPQ80J Amonafide Adenocarcinoma (Cell Line: HCT-15) [2]
Amonafide + Crizotinib DCOEKZ6 Amonafide Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Amonafide + Crizotinib DCSHO14 Amonafide Glioma (Cell Line: SF-295) [2]
Amonafide + Crizotinib DCGHIC2 Amonafide Malignant melanoma (Cell Line: LOX IMVI) [2]
Amonafide + Crizotinib DCUE8G0 Amonafide Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Anastrozole + Crizotinib DC436NK Anastrozole Adenocarcinoma (Cell Line: HCT-15) [2]
Anastrozole + Crizotinib DCFNR71 Anastrozole Amelanotic melanoma (Cell Line: M14) [2]
Anastrozole + Crizotinib DC6FJ4L Anastrozole Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Anastrozole + Crizotinib DCNN07Z Anastrozole Malignant melanoma (Cell Line: LOX IMVI) [2]
Anastrozole + Crizotinib DCXZ8IB Anastrozole Invasive ductal carcinoma (Cell Line: BT-549) [3]
Arfolitixorin + Crizotinib DCS2V86 Arfolitixorin Glioma (Cell Line: SF-295) [2]
Arfolitixorin + Crizotinib DCVT61R Arfolitixorin Adenocarcinoma (Cell Line: HCT-15) [4]
Arfolitixorin + Crizotinib DCXRZZ6 Arfolitixorin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Bafilomycin A1 + Crizotinib DCY02OX Bafilomycin A1 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
BIO-300 + Crizotinib DCIFI8A BIO-300 Chronic myelogenous leukemia (Cell Line: K-562) [2]
BIO-300 + Crizotinib DC3SH90 BIO-300 Glioma (Cell Line: SF-268) [2]
BIO-300 + Crizotinib DC10B8G BIO-300 Papillary renal cell carcinoma (Cell Line: ACHN) [2]
BIO-300 + Crizotinib DCKYF3K BIO-300 Renal cell carcinoma (Cell Line: SN12C) [2]
BIO-300 + Crizotinib DC2OKSY BIO-300 Adenocarcinoma (Cell Line: NCIH23) [4]
BIO-300 + Crizotinib DC6HI5B BIO-300 Adenocarcinoma (Cell Line: HT29) [4]
BIO-300 + Crizotinib DC0YS05 BIO-300 Adenocarcinoma (Cell Line: HCT116) [4]
BIO-300 + Crizotinib DCEH5U0 BIO-300 Adenocarcinoma (Cell Line: SW-620) [4]
BIO-300 + Crizotinib DC3GFBR BIO-300 Malignant melanoma (Cell Line: UACC62) [4]
BIO-300 + Crizotinib DCS0PHK BIO-300 Melanoma (Cell Line: MALME-3M) [4]
BIO-300 + Crizotinib DCWH348 BIO-300 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
BIO-300 + Crizotinib DCJ3UJW BIO-300 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
BIO-300 + Crizotinib DCHBFZJ BIO-300 Prostate carcinoma (Cell Line: PC-3) [4]
Bleomycin + Crizotinib DC08EVO Bleomycin Glioma (Cell Line: SF-295) [2]
Bleomycin + Crizotinib DCSBMJV Bleomycin Adenocarcinoma (Cell Line: HCT-15) [4]
Bleomycin + Crizotinib DCSPDL0 Bleomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Bleomycin + Crizotinib DCMLJY6 Bleomycin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Bleomycin + Crizotinib DCS4G14 Bleomycin Malignant melanoma (Cell Line: LOX IMVI) [4]
Bleomycin + Crizotinib DCUEVX4 Bleomycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Cabazitaxel + Crizotinib DCW36EH Cabazitaxel Adenocarcinoma (Cell Line: NCIH23) [2]
Cabazitaxel + Crizotinib DC6OC5M Cabazitaxel Adenocarcinoma (Cell Line: SW-620) [2]
Cabazitaxel + Crizotinib DCBMHKB Cabazitaxel Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Cabazitaxel + Crizotinib DCWECVX Cabazitaxel Chronic myelogenous leukemia (Cell Line: K-562) [2]
Cabazitaxel + Crizotinib DC1NQG7 Cabazitaxel Glioma (Cell Line: SF-268) [2]
Cabazitaxel + Crizotinib DCQADUF Cabazitaxel Lung adenocarcinoma (Cell Line: EKVX) [2]
Cabazitaxel + Crizotinib DCUA0PN Cabazitaxel Melanoma (Cell Line: MALME-3M) [2]
Cabazitaxel + Crizotinib DCS5I94 Cabazitaxel Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [2]
Cabazitaxel + Crizotinib DCKZGK6 Cabazitaxel Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [2]
Crizotinib + Mechlorethamine DCV0G8A Mechlorethamine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Mechlorethamine DCDI92C Mechlorethamine Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Mechlorethamine DCFZYZA Mechlorethamine Renal cell carcinoma (Cell Line: SN12C) [2]
Crizotinib + Pentostatin DC6EG09 Pentostatin Adenocarcinoma (Cell Line: DU-145) [2]
Crizotinib + Pentostatin DC5U765 Pentostatin Amelanotic melanoma (Cell Line: M14) [2]
Crizotinib + Pentostatin DCO1Y3A Pentostatin Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Pentostatin DCN64D9 Pentostatin Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + Pentostatin DCULBIT Pentostatin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Crizotinib + Pentostatin DCDO3VY Pentostatin Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Pentostatin DCVJ0AN Pentostatin Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Picoplatin DCFQILX Picoplatin Astrocytoma (Cell Line: U251) [2]
Crizotinib + Fulvestrant DCB5QBZ Fulvestrant Adenocarcinoma (Cell Line: DU-145) [2]
Crizotinib + Fulvestrant DCPHGWL Fulvestrant Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Fulvestrant DCB5W68 Fulvestrant Adenocarcinoma (Cell Line: NCIH23) [2]
Crizotinib + Fulvestrant DC2HHR3 Fulvestrant Amelanotic melanoma (Cell Line: M14) [2]
Crizotinib + Fulvestrant DCG3XGK Fulvestrant Astrocytoma (Cell Line: U251) [2]
Crizotinib + Fulvestrant DC7UOWK Fulvestrant Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + Fulvestrant DCWXSRL Fulvestrant Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Crizotinib + Fulvestrant DCK2EUS Fulvestrant Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Fulvestrant DC8PGMC Fulvestrant Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Crizotinib + Fulvestrant DCAK25M Fulvestrant High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [2]
Crizotinib + Fulvestrant DC21XTR Fulvestrant High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Crizotinib + Fulvestrant DCGSS9M Fulvestrant Lung adenocarcinoma (Cell Line: HOP-62) [2]
Crizotinib + Fulvestrant DCZ9KV1 Fulvestrant Lung adenocarcinoma (Cell Line: NCI-H522) [2]
Crizotinib + Fulvestrant DC0VGDC Fulvestrant Melanoma (Cell Line: UACC-257) [2]
Crizotinib + Fulvestrant DC4F8LB Fulvestrant Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Crizotinib + Gefitinib DC1TVHU Gefitinib Adenocarcinoma (Cell Line: DU-145) [2]
Crizotinib + Gefitinib DC1KF63 Gefitinib Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Gefitinib DC4JRWH Gefitinib Adenocarcinoma (Cell Line: A549) [2]
Crizotinib + Gefitinib DCZJIFR Gefitinib Adenocarcinoma (Cell Line: NCIH23) [2]
Crizotinib + Gefitinib DC6CMQS Gefitinib Adenocarcinoma (Cell Line: HCT-15) [2]
Crizotinib + Gefitinib DCU6OUW Gefitinib Amelanotic melanoma (Cell Line: M14) [2]
Crizotinib + Gefitinib DCX2I7D Gefitinib Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + Gefitinib DCARD1Y Gefitinib Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + Gefitinib DC7304N Gefitinib Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Crizotinib + Gefitinib DCKNBPZ Gefitinib Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Gefitinib DC46KHN Gefitinib Clear cell renal cell carcinoma (Cell Line: A498) [2]
Crizotinib + Gefitinib DCT1S18 Gefitinib Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Crizotinib + Gefitinib DCINCQQ Gefitinib Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + Gefitinib DCDFGF4 Gefitinib Glioblastoma (Cell Line: SNB-75) [2]
Crizotinib + Gefitinib DCARPXT Gefitinib Glioma (Cell Line: SF-539) [2]
Crizotinib + Gefitinib DCG6SKE Gefitinib Glioma (Cell Line: SF-268) [2]
Crizotinib + Gefitinib DC8M5Y4 Gefitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [2]
Crizotinib + Gefitinib DCMD9FS Gefitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Crizotinib + Gefitinib DC6HL3C Gefitinib Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Gefitinib DC3Y7CT Gefitinib Lung adenocarcinoma (Cell Line: EKVX) [2]
Crizotinib + Gefitinib DCVCIPQ Gefitinib Lung adenocarcinoma (Cell Line: HOP-62) [2]
Crizotinib + Gefitinib DCFU1L5 Gefitinib Lung adenocarcinoma (Cell Line: NCI-H522) [2]
Crizotinib + Gefitinib DCAMODK Gefitinib Melanoma (Cell Line: UACC-257) [2]
Crizotinib + Gefitinib DC3SS31 Gefitinib Melanoma (Cell Line: SK-MEL-2) [2]
Crizotinib + Gefitinib DCK0PU7 Gefitinib Melanoma (Cell Line: MALME-3M) [2]
Crizotinib + Gefitinib DCEZJP5 Gefitinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Crizotinib + Gefitinib DCQHOYY Gefitinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [2]
Crizotinib + Gefitinib DCK4SM1 Gefitinib Non-small cell lung carcinoma (Cell Line: HOP-92) [2]
Crizotinib + Gefitinib DC00W1P Gefitinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Crizotinib + Gefitinib DCWF6S7 Gefitinib Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Gefitinib DCO19VA Gefitinib Prostate carcinoma (Cell Line: PC-3) [2]
Crizotinib + Gefitinib DCHMTX0 Gefitinib Renal cell carcinoma (Cell Line: SN12C) [2]
Crizotinib + Ruxolitinib DCUTJVH Ruxolitinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Ruxolitinib DCIWZ94 Ruxolitinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Crizotinib + Hepzato DCS4I3K Hepzato Amelanotic melanoma (Cell Line: M14) [2]
Crizotinib + Hepzato DCYHVUO Hepzato Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + Hepzato DCBPIA8 Hepzato Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Ixabepilone DCQJCZ2 Ixabepilone Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Crizotinib + Ixabepilone DCO4DKK Ixabepilone Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + Ixabepilone DC4Y55I Ixabepilone Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Crizotinib + Ixabepilone DCES29K Ixabepilone Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Crizotinib + Ixabepilone DCO5XHI Ixabepilone Lung adenocarcinoma (Cell Line: MDA-MB-231) [2]
Crizotinib + Dactinomycin DCGBFJV Dactinomycin Adenocarcinoma (Cell Line: DU-145) [2]
Crizotinib + Dactinomycin DCYXQP3 Dactinomycin Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Dactinomycin DCSY44I Dactinomycin Adenocarcinoma (Cell Line: NCIH23) [2]
Crizotinib + Dactinomycin DCBJROT Dactinomycin Adenocarcinoma (Cell Line: A549) [2]
Crizotinib + Dactinomycin DCICKID Dactinomycin Adenocarcinoma (Cell Line: HCT-15) [2]
Crizotinib + Dactinomycin DCV4ED5 Dactinomycin Adenocarcinoma (Cell Line: HCC-2998) [2]
Crizotinib + Dactinomycin DC4CHLC Dactinomycin Adenocarcinoma (Cell Line: HCT116) [2]
Crizotinib + Dactinomycin DC72SVJ Dactinomycin Adenocarcinoma (Cell Line: HT29) [2]
Crizotinib + Dactinomycin DCTM2VR Dactinomycin Adenocarcinoma (Cell Line: SW-620) [2]
Crizotinib + Dactinomycin DCT7N31 Dactinomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Crizotinib + Dactinomycin DCJTW71 Dactinomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Dactinomycin DCP08BD Dactinomycin Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
Crizotinib + Dactinomycin DCDWN5V Dactinomycin Amelanotic melanoma (Cell Line: M14) [2]
Crizotinib + Dactinomycin DCTIF62 Dactinomycin Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + Dactinomycin DCJ3QW9 Dactinomycin Astrocytoma (Cell Line: U251) [2]
Crizotinib + Dactinomycin DC9UNYK Dactinomycin Astrocytoma (Cell Line: SNB-19) [2]
Crizotinib + Dactinomycin DCOAPGG Dactinomycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Crizotinib + Dactinomycin DCTZMB9 Dactinomycin Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + Dactinomycin DCXXGZ0 Dactinomycin Clear cell renal cell carcinoma (Cell Line: A498) [2]
Crizotinib + Dactinomycin DCHCD94 Dactinomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Dactinomycin DC6JQU9 Dactinomycin Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Crizotinib + Dactinomycin DCX161V Dactinomycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Crizotinib + Dactinomycin DCYYU14 Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + Dactinomycin DCA5OAG Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Crizotinib + Dactinomycin DCLK35J Dactinomycin Glioblastoma (Cell Line: SNB-75) [2]
Crizotinib + Dactinomycin DCQ8ZM2 Dactinomycin Glioma (Cell Line: SF-295) [2]
Crizotinib + Dactinomycin DC3LUSM Dactinomycin Glioma (Cell Line: SF-268) [2]
Crizotinib + Dactinomycin DCYHDXY Dactinomycin Glioma (Cell Line: SF-539) [2]
Crizotinib + Dactinomycin DCC3GF7 Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Crizotinib + Dactinomycin DCPFL6Q Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [2]
Crizotinib + Dactinomycin DCRVMVX Dactinomycin Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Dactinomycin DCQZ8QM Dactinomycin Lung adenocarcinoma (Cell Line: HOP-62) [2]
Crizotinib + Dactinomycin DCP5VHA Dactinomycin Lung adenocarcinoma (Cell Line: EKVX) [2]
Crizotinib + Dactinomycin DCWCJKU Dactinomycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [2]
Crizotinib + Dactinomycin DCSOSPE Dactinomycin Lung adenocarcinoma (Cell Line: NCI-H522) [2]
Crizotinib + Dactinomycin DCUCW5T Dactinomycin Malignant melanoma (Cell Line: LOX IMVI) [2]
Crizotinib + Dactinomycin DCH6KZT Dactinomycin Malignant melanoma (Cell Line: UACC62) [2]
Crizotinib + Dactinomycin DCO3NSG Dactinomycin Melanoma (Cell Line: MALME-3M) [2]
Crizotinib + Dactinomycin DCFMXX9 Dactinomycin Melanoma (Cell Line: UACC-257) [2]
Crizotinib + Dactinomycin DCV2I0W Dactinomycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Crizotinib + Dactinomycin DCC6S8H Dactinomycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [2]
Crizotinib + Dactinomycin DC5A4QV Dactinomycin Non-small cell lung carcinoma (Cell Line: HOP-92) [2]
Crizotinib + Dactinomycin DCC20BU Dactinomycin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Crizotinib + Dactinomycin DCAFED8 Dactinomycin Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Crizotinib + Dactinomycin DCJYOZB Dactinomycin Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Dactinomycin DCQHMBK Dactinomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [2]
Crizotinib + Dactinomycin DC3AYBY Dactinomycin Prostate carcinoma (Cell Line: PC-3) [2]
Crizotinib + Dactinomycin DCTCI7X Dactinomycin Renal cell carcinoma (Cell Line: SN12C) [2]
Crizotinib + DFN-15 DC2FXZN DFN-15 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + DFN-15 DCZX3D3 DFN-15 Amelanotic melanoma (Cell Line: M14) [2]
Crizotinib + DFN-15 DCO79DM DFN-15 Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Crizotinib + DFN-15 DCF6AZ3 DFN-15 Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + DFN-15 DCSIWCZ DFN-15 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Crizotinib + DFN-15 DCZ2KMJ DFN-15 High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Crizotinib + DFN-15 DC52GI0 DFN-15 Lung adenocarcinoma (Cell Line: HOP-62) [2]
Crizotinib + DFN-15 DCKSBSY DFN-15 Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Lapatinib DCO6T67 Lapatinib Astrocytoma (Cell Line: U251) [2]
Crizotinib + Lapatinib DCO2IS8 Lapatinib Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + Lapatinib DCNGCN0 Lapatinib Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Carfilzomib DCUT6I6 Carfilzomib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Crizotinib + PMID28460551-Compound-2 DC5SUC0 PMID28460551-Compound-2 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Crizotinib + PMID28460551-Compound-2 DCKXCLC PMID28460551-Compound-2 Astrocytoma (Cell Line: SNB-19) [2]
Crizotinib + PMID28460551-Compound-2 DCBX6QN PMID28460551-Compound-2 Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + PMID28460551-Compound-2 DCR9982 PMID28460551-Compound-2 Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + PMID28460551-Compound-2 DCARIRI PMID28460551-Compound-2 Lung adenocarcinoma (Cell Line: MDA-MB-231) [2]
Crizotinib + PMID28460551-Compound-2 DCIFMLV PMID28460551-Compound-2 Lung adenocarcinoma (Cell Line: NCI-H522) [2]
Crizotinib + PMID28460551-Compound-2 DCK6AHJ PMID28460551-Compound-2 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [2]
Crizotinib + PMID28460551-Compound-2 DCD4CK5 PMID28460551-Compound-2 Renal cell carcinoma (Cell Line: UO-31) [2]
Crizotinib + LIAROZOLE DCJT59J LIAROZOLE Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Methotrexate DCCQIDC Methotrexate High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Crizotinib + Vismodegib DCHP0BT Vismodegib Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Vismodegib DCV6TAO Vismodegib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Vismodegib DCALXY6 Vismodegib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Crizotinib + Vismodegib DCBMTU1 Vismodegib Melanoma (Cell Line: UACC-257) [2]
Crizotinib + Isoniazid DCFKICD Isoniazid Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Isoniazid DC47XP4 Isoniazid Astrocytoma (Cell Line: U251) [2]
Crizotinib + Isoniazid DCMV6GQ Isoniazid Glioma (Cell Line: SF-539) [2]
Crizotinib + Isoniazid DCD0GZR Isoniazid High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Crizotinib + Isoniazid DC4YEMQ Isoniazid Melanoma (Cell Line: UACC-257) [2]
Crizotinib + Isoniazid DCTTUJS Isoniazid Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Arsenic trioxide DCZ33RS Arsenic trioxide Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Arsenic trioxide DC5Z19F Arsenic trioxide Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Vemurafenib DCMCEI9 Vemurafenib Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Vemurafenib DCBJOQY Vemurafenib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Vemurafenib DCDINB7 Vemurafenib Malignant melanoma (Cell Line: UACC62) [2]
Crizotinib + Vemurafenib DCI8CIP Vemurafenib Malignant melanoma (Cell Line: LOX IMVI) [2]
Crizotinib + Alvespimycin hydrochloride DCO945F Alvespimycin hydrochloride Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Crizotinib + Lenalidomide DCN52D8 Lenalidomide Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Plicamycin DCXM143 Plicamycin Adenocarcinoma (Cell Line: DU-145) [2]
Crizotinib + Plicamycin DCKV3NM Plicamycin Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Plicamycin DCPVFAH Plicamycin Adenocarcinoma (Cell Line: HCT116) [2]
Crizotinib + Plicamycin DC55L55 Plicamycin Adenocarcinoma (Cell Line: HCC-2998) [2]
Crizotinib + Plicamycin DCHPEDV Plicamycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Plicamycin DCOS0DF Plicamycin Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
Crizotinib + Plicamycin DCR0DAO Plicamycin Amelanotic melanoma (Cell Line: M14) [2]
Crizotinib + Plicamycin DC9WV79 Plicamycin Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + Plicamycin DCUHW44 Plicamycin Astrocytoma (Cell Line: U251) [2]
Crizotinib + Plicamycin DCT9OYY Plicamycin Astrocytoma (Cell Line: SNB-19) [2]
Crizotinib + Plicamycin DCG16DE Plicamycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Crizotinib + Plicamycin DCHQMJ6 Plicamycin Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + Plicamycin DC1J8QM Plicamycin Clear cell renal cell carcinoma (Cell Line: A498) [2]
Crizotinib + Plicamycin DC8E6WP Plicamycin Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Plicamycin DCJUB8I Plicamycin Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Crizotinib + Plicamycin DC8HPW1 Plicamycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Crizotinib + Plicamycin DCIZ3GN Plicamycin Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + Plicamycin DC1Y6RV Plicamycin Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Crizotinib + Plicamycin DCVPUYT Plicamycin Glioblastoma (Cell Line: SNB-75) [2]
Crizotinib + Plicamycin DC90BL6 Plicamycin Glioma (Cell Line: SF-295) [2]
Crizotinib + Plicamycin DC8VIJI Plicamycin Glioma (Cell Line: SF-268) [2]
Crizotinib + Plicamycin DCSUDOW Plicamycin Glioma (Cell Line: SF-539) [2]
Crizotinib + Plicamycin DC55RQG Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Crizotinib + Plicamycin DCWC2L6 Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [2]
Crizotinib + Plicamycin DCNOP70 Plicamycin Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Plicamycin DCTCN6L Plicamycin Lung adenocarcinoma (Cell Line: HOP-62) [2]
Crizotinib + Plicamycin DCIUPRB Plicamycin Lung adenocarcinoma (Cell Line: EKVX) [2]
Crizotinib + Plicamycin DCLJEUD Plicamycin Malignant melanoma (Cell Line: UACC62) [2]
Crizotinib + Plicamycin DCLS8EE Plicamycin Melanoma (Cell Line: MALME-3M) [2]
Crizotinib + Plicamycin DCZUU50 Plicamycin Melanoma (Cell Line: UACC-257) [2]
Crizotinib + Plicamycin DC9MK6R Plicamycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Crizotinib + Plicamycin DCEX8AR Plicamycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [2]
Crizotinib + Plicamycin DC3MRU4 Plicamycin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Crizotinib + Plicamycin DC85ME0 Plicamycin Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Crizotinib + Plicamycin DC04PH7 Plicamycin Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Plicamycin DCWMO3L Plicamycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [2]
Crizotinib + Plicamycin DCJ3GO6 Plicamycin Renal cell carcinoma (Cell Line: UO-31) [2]
Crizotinib + Plicamycin DC7JS5M Plicamycin Renal cell carcinoma (Cell Line: SN12C) [2]
Crizotinib + Nilotinib DCQC60I Nilotinib Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Nilotinib DC2MKY0 Nilotinib Amelanotic melanoma (Cell Line: M14) [2]
Crizotinib + Nilotinib DCX41HT Nilotinib Astrocytoma (Cell Line: U251) [2]
Crizotinib + Nilotinib DCORTTP Nilotinib Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + Nilotinib DCY7YMI Nilotinib Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Nilotinib DCEG6Z2 Nilotinib Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + Nilotinib DCIK2C7 Nilotinib Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Nilotinib DC10PJU Nilotinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [2]
Crizotinib + Nilotinib DCDHVW8 Nilotinib Prostate carcinoma (Cell Line: PC-3) [2]
Crizotinib + Thioguanine DCSKFN0 Thioguanine Adenocarcinoma (Cell Line: DU-145) [2]
Crizotinib + Thioguanine DCQXLE6 Thioguanine Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Thioguanine DC9SG81 Thioguanine Adenocarcinoma (Cell Line: NCIH23) [2]
Crizotinib + Thioguanine DCVF4ZT Thioguanine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Thioguanine DC8M6N5 Thioguanine Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + Thioguanine DCHMUQJ Thioguanine Astrocytoma (Cell Line: U251) [2]
Crizotinib + Thioguanine DCLPWME Thioguanine Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Thioguanine DCF6WCE Thioguanine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Crizotinib + Thioguanine DC5CVPM Thioguanine Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Crizotinib + Thioguanine DCRDAA1 Thioguanine Glioma (Cell Line: SF-539) [2]
Crizotinib + Thioguanine DCURH2M Thioguanine Glioma (Cell Line: SF-295) [2]
Crizotinib + Thioguanine DCEM0EB Thioguanine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Crizotinib + Thioguanine DCKA0EQ Thioguanine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Crizotinib + Thioguanine DC7L6G7 Thioguanine Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Thioguanine DC2BNUZ Thioguanine Lung adenocarcinoma (Cell Line: HOP-62) [2]
Crizotinib + Thioguanine DCZHL5C Thioguanine Malignant melanoma (Cell Line: LOX IMVI) [2]
Crizotinib + Thioguanine DCWAPW6 Thioguanine Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Crizotinib + Thioguanine DCLEPV3 Thioguanine Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Thioguanine DCJARS0 Thioguanine Renal cell carcinoma (Cell Line: SN12C) [2]
Crizotinib + Triapine DCG38GN Triapine Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Triapine DC8J5HW Triapine Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Crizotinib + ABIRATERONE DCF3O28 ABIRATERONE Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + ABIRATERONE DCQ49CZ ABIRATERONE Adenocarcinoma (Cell Line: NCIH23) [2]
Crizotinib + ABIRATERONE DCX83L8 ABIRATERONE Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + ABIRATERONE DC18ZQC ABIRATERONE Amelanotic melanoma (Cell Line: M14) [2]
Crizotinib + ABIRATERONE DC3PJU8 ABIRATERONE Astrocytoma (Cell Line: U251) [2]
Crizotinib + ABIRATERONE DCDRP14 ABIRATERONE Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Crizotinib + ABIRATERONE DCK5EF4 ABIRATERONE Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Crizotinib + ABIRATERONE DCZKZ2R ABIRATERONE Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + ABIRATERONE DCWKTT7 ABIRATERONE High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Crizotinib + ABIRATERONE DC05H9W ABIRATERONE Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + ABIRATERONE DC8DTBE ABIRATERONE Lung adenocarcinoma (Cell Line: HOP-62) [2]
Crizotinib + ABIRATERONE DC2N56W ABIRATERONE Malignant melanoma (Cell Line: LOX IMVI) [2]
Crizotinib + ABIRATERONE DCYIZHJ ABIRATERONE Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Crizotinib + 10-hydroxycamptothecin DCXPA25 10-hydroxycamptothecin Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + 10-hydroxycamptothecin DCB4EG6 10-hydroxycamptothecin Astrocytoma (Cell Line: SNB-19) [2]
Crizotinib + 10-hydroxycamptothecin DCB5W32 10-hydroxycamptothecin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Crizotinib + 10-hydroxycamptothecin DCIZJHQ 10-hydroxycamptothecin Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + 10-hydroxycamptothecin DCIJ8CM 10-hydroxycamptothecin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Crizotinib + 10-hydroxycamptothecin DCITZAW 10-hydroxycamptothecin Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + 10-hydroxycamptothecin DCFVWMS 10-hydroxycamptothecin Lung adenocarcinoma (Cell Line: MDA-MB-231) [2]
Crizotinib + 10-hydroxycamptothecin DCIRK7X 10-hydroxycamptothecin Prostate carcinoma (Cell Line: PC-3) [2]
Crizotinib + Topetecan DC6W1L9 Topetecan Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + Amonafide DC79UG9 Amonafide Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Amonafide DCYLJ8E Amonafide Astrocytoma (Cell Line: SNB-19) [2]
Crizotinib + Amonafide DCV43L8 Amonafide Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Amonafide DCVM6AV Amonafide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Crizotinib + Amonafide DCMKZWP Amonafide Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Amonafide DC7WJ1M Amonafide Renal cell carcinoma (Cell Line: SN12C) [2]
Crizotinib + Pralatrexate DC4772R Pralatrexate Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Pralatrexate DCBZ196 Pralatrexate Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Crizotinib + Pralatrexate DCMACSR Pralatrexate High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Crizotinib + Pralatrexate DCPWIWK Pralatrexate High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [2]
Crizotinib + Selumetinib DCWNG5L Selumetinib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Crizotinib + Terameprocol DCULP1N Terameprocol Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Terameprocol DCETFZJ Terameprocol Adenocarcinoma (Cell Line: NCIH23) [2]
Crizotinib + Terameprocol DCU95N5 Terameprocol Adenocarcinoma (Cell Line: HCT-15) [2]
Crizotinib + Terameprocol DCD9H67 Terameprocol Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Terameprocol DCOL92D Terameprocol Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Terameprocol DCYXQ80 Terameprocol Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + Terameprocol DC2BCFJ Terameprocol Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Crizotinib + Terameprocol DCVNHXL Terameprocol High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [2]
Crizotinib + Terameprocol DC88SSR Terameprocol High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Crizotinib + Terameprocol DCH41TQ Terameprocol Lung adenocarcinoma (Cell Line: HOP-62) [2]
Crizotinib + Terameprocol DCBHNKI Terameprocol Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Crizotinib + Terameprocol DC47GF0 Terameprocol Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Crizotinib + Terameprocol DCRP2PC Terameprocol Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Terameprocol DC39DX3 Terameprocol Renal cell carcinoma (Cell Line: UO-31) [2]
Crizotinib + SCH 727965 DC8M3SZ SCH 727965 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Crizotinib + SCH 727965 DCC3WDX SCH 727965 Astrocytoma (Cell Line: U251) [2]
Crizotinib + SCH 727965 DCNOFQ3 SCH 727965 Malignant melanoma (Cell Line: UACC62) [2]
Crizotinib + SCH 727965 DCKT5HY SCH 727965 Melanoma (Cell Line: UACC-257) [2]
Crizotinib + SCH 727965 DC1171U SCH 727965 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Crizotinib + Ifosfamide DCTT74M Ifosfamide Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Ifosfamide DC01E1V Ifosfamide Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Ifosfamide DC12ECP Ifosfamide Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Plinabulin DCVD6FO Plinabulin Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Crizotinib + Dexrazoxane DC3ASB1 Dexrazoxane Adenocarcinoma (Cell Line: HCT-15) [2]
Crizotinib + Dexrazoxane DC7UPJH Dexrazoxane Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Crizotinib + Dexrazoxane DCOBLDQ Dexrazoxane Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + Dexrazoxane DCYRWO1 Dexrazoxane High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Crizotinib + Dexrazoxane DCH5QDR Dexrazoxane Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Docetaxel DCP94OL Docetaxel Adenocarcinoma (Cell Line: NCIH23) [2]
Crizotinib + Docetaxel DCRNS9U Docetaxel Adenocarcinoma (Cell Line: A549) [2]
Crizotinib + Docetaxel DCE8M2E Docetaxel Adenocarcinoma (Cell Line: HCC-2998) [2]
Crizotinib + Docetaxel DCQBU14 Docetaxel Adenocarcinoma (Cell Line: HCT116) [2]
Crizotinib + Docetaxel DCT21SD Docetaxel Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Docetaxel DCWV777 Docetaxel Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + Docetaxel DCF7ID4 Docetaxel Astrocytoma (Cell Line: SNB-19) [2]
Crizotinib + Docetaxel DCIQ2GK Docetaxel Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + Docetaxel DCUKMNT Docetaxel Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Crizotinib + Docetaxel DCFFGBO Docetaxel Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Docetaxel DCEJ0U4 Docetaxel Lung adenocarcinoma (Cell Line: MDA-MB-231) [2]
Crizotinib + Docetaxel DCRDRG4 Docetaxel Prostate carcinoma (Cell Line: PC-3) [2]
Crizotinib + Raloxifene DCUEETS Raloxifene Adenocarcinoma (Cell Line: DU-145) [2]
Crizotinib + Raloxifene DCQGOWQ Raloxifene Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Raloxifene DCXA0FE Raloxifene Adenocarcinoma (Cell Line: NCIH23) [2]
Crizotinib + Raloxifene DCEKFR2 Raloxifene Adenocarcinoma (Cell Line: HCT-15) [2]
Crizotinib + Raloxifene DCDOALC Raloxifene Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Raloxifene DC2QJ57 Raloxifene Amelanotic melanoma (Cell Line: M14) [2]
Crizotinib + Raloxifene DCVC52W Raloxifene Astrocytoma (Cell Line: U251) [2]
Crizotinib + Raloxifene DC96UYW Raloxifene Astrocytoma (Cell Line: SNB-19) [2]
Crizotinib + Raloxifene DCJCXRI Raloxifene Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + Raloxifene DCRYXSH Raloxifene Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Crizotinib + Raloxifene DCAH9WZ Raloxifene Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + Raloxifene DCEU09E Raloxifene Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Crizotinib + Raloxifene DCFBD4P Raloxifene Glioblastoma (Cell Line: SNB-75) [2]
Crizotinib + Raloxifene DCJVX0Z Raloxifene Glioma (Cell Line: SF-268) [2]
Crizotinib + Raloxifene DC1LJR2 Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [2]
Crizotinib + Raloxifene DCY9JKO Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Crizotinib + Raloxifene DCUUGNF Raloxifene Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Raloxifene DCGAYF8 Raloxifene Lung adenocarcinoma (Cell Line: HOP-62) [2]
Crizotinib + Raloxifene DCWJ2VV Raloxifene Melanoma (Cell Line: UACC-257) [2]
Crizotinib + Raloxifene DC3YNED Raloxifene Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Crizotinib + Raloxifene DC7LWEW Raloxifene Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Crizotinib + Raloxifene DCX3B2O Raloxifene Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Raloxifene DC91RMJ Raloxifene Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [2]
Crizotinib + Raloxifene DCWTTVS Raloxifene Renal cell carcinoma (Cell Line: SN12C) [2]
Crizotinib + Marizomib DCQQ424 Marizomib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Crizotinib + Bendamustine hydrochloride DCD7E5R Bendamustine hydrochloride Adenocarcinoma (Cell Line: A549) [2]
Crizotinib + Bendamustine hydrochloride DCARVJR Bendamustine hydrochloride Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Crizotinib + Bendamustine hydrochloride DC66JG2 Bendamustine hydrochloride Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Bendamustine hydrochloride DCND7XR Bendamustine hydrochloride Amelanotic melanoma (Cell Line: M14) [2]
Crizotinib + Bendamustine hydrochloride DCYXNP1 Bendamustine hydrochloride Astrocytoma (Cell Line: SNB-19) [2]
Crizotinib + Bendamustine hydrochloride DCHSBCF Bendamustine hydrochloride Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + Bendamustine hydrochloride DCOWTQS Bendamustine hydrochloride Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Crizotinib + Bendamustine hydrochloride DCQF5F2 Bendamustine hydrochloride Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + Bendamustine hydrochloride DC08QAN Bendamustine hydrochloride High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Crizotinib + Bendamustine hydrochloride DCC0ASU Bendamustine hydrochloride Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Bendamustine hydrochloride DCOV40W Bendamustine hydrochloride Melanoma (Cell Line: UACC-257) [2]
Crizotinib + Bendamustine hydrochloride DCALOW4 Bendamustine hydrochloride Prostate carcinoma (Cell Line: PC-3) [2]
Crizotinib + Bendamustine hydrochloride DCF338K Bendamustine hydrochloride Renal cell carcinoma (Cell Line: UO-31) [2]
Crizotinib + Trifluridine DCZEN8S Trifluridine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Trifluridine DC8PW5T Trifluridine Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + Trifluridine DC0EVHW Trifluridine Astrocytoma (Cell Line: SNB-19) [2]
Crizotinib + Trifluridine DCUIVOY Trifluridine Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + Trifluridine DC1OZSS Trifluridine Lung adenocarcinoma (Cell Line: NCI-H522) [2]
Crizotinib + Trifluridine DCYR0AK Trifluridine Renal cell carcinoma (Cell Line: SN12C) [2]
Crizotinib + Sirolimus DCK02G8 Sirolimus Adenocarcinoma (Cell Line: DU-145) [2]
Crizotinib + Sirolimus DCKE0ZK Sirolimus Adenocarcinoma (Cell Line: NCIH23) [2]
Crizotinib + Sirolimus DCJJP8W Sirolimus Adenocarcinoma (Cell Line: HT29) [2]
Crizotinib + Sirolimus DCJZPSL Sirolimus Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Crizotinib + Sirolimus DCXTOM0 Sirolimus Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
Crizotinib + Sirolimus DC42DMP Sirolimus Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + Sirolimus DCG7EWN Sirolimus Astrocytoma (Cell Line: SNB-19) [2]
Crizotinib + Sirolimus DCF3YRN Sirolimus Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Crizotinib + Sirolimus DCXV5VW Sirolimus Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Crizotinib + Sirolimus DC3TCN8 Sirolimus Clear cell renal cell carcinoma (Cell Line: A498) [2]
Crizotinib + Sirolimus DC5KXCY Sirolimus Glioma (Cell Line: SF-268) [2]
Crizotinib + Sirolimus DCV9LCM Sirolimus High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [2]
Crizotinib + Sirolimus DCZOFJR Sirolimus Lung adenocarcinoma (Cell Line: EKVX) [2]
Crizotinib + Sirolimus DC8U72H Sirolimus Malignant melanoma (Cell Line: LOX IMVI) [2]
Crizotinib + Sirolimus DCILAWY Sirolimus Melanoma (Cell Line: SK-MEL-2) [2]
Crizotinib + Sirolimus DC47MFH Sirolimus Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [2]
Crizotinib + Sirolimus DCQ01A4 Sirolimus Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Crizotinib + Sirolimus DCZ25C4 Sirolimus Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [2]
Crizotinib + Sirolimus DCTLRXZ Sirolimus Renal cell carcinoma (Cell Line: SN12C) [2]
Crizotinib + Letrozole DC1DFGF Letrozole Adenocarcinoma (Cell Line: DU-145) [2]
Crizotinib + Letrozole DC368IF Letrozole Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Letrozole DCM5SZN Letrozole Amelanotic melanoma (Cell Line: M14) [2]
Crizotinib + Letrozole DCKDVGI Letrozole Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Crizotinib + Letrozole DCQ04HM Letrozole Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + Letrozole DC8WTCI Letrozole Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Crizotinib + Letrozole DCK25MM Letrozole Melanoma (Cell Line: UACC-257) [2]
Crizotinib + Letrozole DCQXS1U Letrozole Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Crizotinib + Letrozole DCC91IW Letrozole Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Crizotinib + Letrozole DCA2TEP Letrozole Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Mitomycin DCZR22K Mitomycin Adenocarcinoma (Cell Line: SW-620) [2]
Crizotinib + Mitomycin DCK75OP Mitomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Crizotinib + Mitomycin DC8MJP2 Mitomycin Astrocytoma (Cell Line: SNB-19) [2]
Crizotinib + Mitomycin DCHHZZ1 Mitomycin Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Crizotinib + Mitomycin DCOJHC4 Mitomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Mitomycin DC8NSZB Mitomycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Crizotinib + Mitomycin DC0KBDX Mitomycin Glioblastoma (Cell Line: SNB-75) [2]
Crizotinib + Mitomycin DCXDJFT Mitomycin Glioma (Cell Line: SF-268) [2]
Crizotinib + Mitomycin DCVIY00 Mitomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Crizotinib + Mitomycin DCT9KT5 Mitomycin Malignant melanoma (Cell Line: LOX IMVI) [2]
Crizotinib + Mitomycin DCQ5A0M Mitomycin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Crizotinib + Mitomycin DCVRCEL Mitomycin Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Mitomycin DCKX38X Mitomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [2]
Crizotinib + SY-1425 DCSBEG4 SY-1425 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Crizotinib + SY-1425 DCRCFMU SY-1425 Melanoma (Cell Line: MALME-3M) [2]
Crizotinib + SY-1425 DC4OIB1 SY-1425 Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Crizotinib + Uracil mustard DCKX5GQ Uracil mustard Adenocarcinoma (Cell Line: DU-145) [2]
Crizotinib + Uracil mustard DCC5PPK Uracil mustard Adenocarcinoma (Cell Line: NCIH23) [2]
Crizotinib + Uracil mustard DCJW3D1 Uracil mustard Adenocarcinoma (Cell Line: HCC-2998) [2]
Crizotinib + Uracil mustard DCEXTKY Uracil mustard Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Uracil mustard DCUM9V9 Uracil mustard Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + Uracil mustard DCPWPDP Uracil mustard Astrocytoma (Cell Line: SNB-19) [2]
Crizotinib + Uracil mustard DC54TVH Uracil mustard Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Crizotinib + Uracil mustard DCRXO5U Uracil mustard Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + Uracil mustard DCO90FX Uracil mustard Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Uracil mustard DC4TG70 Uracil mustard Clear cell renal cell carcinoma (Cell Line: A498) [2]
Crizotinib + Uracil mustard DCL5XN2 Uracil mustard Glioblastoma (Cell Line: SNB-75) [2]
Crizotinib + Uracil mustard DC9M2Z9 Uracil mustard Glioma (Cell Line: SF-295) [2]
Crizotinib + Uracil mustard DCPSA9N Uracil mustard Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Uracil mustard DC8Q80N Uracil mustard Lung adenocarcinoma (Cell Line: EKVX) [2]
Crizotinib + Uracil mustard DCQ0R01 Uracil mustard Lung adenocarcinoma (Cell Line: NCI-H522) [2]
Crizotinib + Uracil mustard DCDD2C9 Uracil mustard Malignant melanoma (Cell Line: UACC62) [2]
Crizotinib + Uracil mustard DC1O5W0 Uracil mustard Melanoma (Cell Line: SK-MEL-2) [2]
Crizotinib + Uracil mustard DC5T1U4 Uracil mustard Non-small cell lung carcinoma (Cell Line: HOP-92) [2]
Crizotinib + Uracil mustard DC966T8 Uracil mustard Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Crizotinib + Uracil mustard DCY4YAE Uracil mustard Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Crizotinib + Uracil mustard DCSE46B Uracil mustard Renal cell carcinoma (Cell Line: SN12C) [2]
Crizotinib + Vincristine DCJXL4P Vincristine Adenocarcinoma (Cell Line: HCT-15) [2]
Crizotinib + Vincristine DCDCO2M Vincristine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Crizotinib + Vincristine DCT3NOA Vincristine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Vincristine DC30A64 Vincristine Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
Crizotinib + Vincristine DC3KQW9 Vincristine Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + Vincristine DCAWKQ9 Vincristine Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Crizotinib + Vincristine DCSM9MF Vincristine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Crizotinib + Vincristine DCF3ODJ Vincristine Glioma (Cell Line: SF-295) [2]
Crizotinib + Vincristine DCK5WQK Vincristine Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Vincristine DCDHGEZ Vincristine Lung adenocarcinoma (Cell Line: NCI-H522) [2]
Crizotinib + Arfolitixorin DCCEAUR Arfolitixorin Adenocarcinoma (Cell Line: DU-145) [2]
Crizotinib + Arfolitixorin DCHACOS Arfolitixorin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Arfolitixorin DCCLCMJ Arfolitixorin Astrocytoma (Cell Line: U251) [2]
Crizotinib + Arfolitixorin DCC5QYX Arfolitixorin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Crizotinib + Arfolitixorin DCAR13R Arfolitixorin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Crizotinib + Arfolitixorin DCJY36M Arfolitixorin Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Arfolitixorin DCQWANF Arfolitixorin Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Arfolitixorin DC15G1G Arfolitixorin Renal cell carcinoma (Cell Line: SN12C) [2]
Crizotinib + BIO-300 DC2UY2A BIO-300 Adenocarcinoma (Cell Line: DU-145) [2]
Crizotinib + BIO-300 DC55XAV BIO-300 Adenocarcinoma (Cell Line: NCIH23) [2]
Crizotinib + BIO-300 DCTW16N BIO-300 Adenocarcinoma (Cell Line: A549) [2]
Crizotinib + BIO-300 DCMPORQ BIO-300 Adenocarcinoma (Cell Line: HT29) [2]
Crizotinib + BIO-300 DC4V59F BIO-300 Adenocarcinoma (Cell Line: HCT116) [2]
Crizotinib + BIO-300 DCEJKQC BIO-300 Adenocarcinoma (Cell Line: HCT-15) [2]
Crizotinib + BIO-300 DCFHGAX BIO-300 Adenocarcinoma (Cell Line: HCC-2998) [2]
Crizotinib + BIO-300 DCG2HKI BIO-300 Adenocarcinoma (Cell Line: SW-620) [2]
Crizotinib + BIO-300 DCU0MO4 BIO-300 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Crizotinib + BIO-300 DC2HJEY BIO-300 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + BIO-300 DCKFGZV BIO-300 Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
Crizotinib + BIO-300 DC2FQUV BIO-300 Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + BIO-300 DC20I6M BIO-300 Astrocytoma (Cell Line: SNB-19) [2]
Crizotinib + BIO-300 DC3LFJ7 BIO-300 Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Crizotinib + BIO-300 DCM5ORP BIO-300 Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + BIO-300 DCP433B BIO-300 Clear cell renal cell carcinoma (Cell Line: A498) [2]
Crizotinib + BIO-300 DCPNKBQ BIO-300 Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Crizotinib + BIO-300 DC0TYGA BIO-300 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Crizotinib + BIO-300 DCDSOD6 BIO-300 Glioblastoma (Cell Line: SNB-75) [2]
Crizotinib + BIO-300 DCLLCAP BIO-300 Glioma (Cell Line: SF-295) [2]
Crizotinib + BIO-300 DCLZUQH BIO-300 Glioma (Cell Line: SF-268) [2]
Crizotinib + BIO-300 DC7TMA8 BIO-300 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Crizotinib + BIO-300 DCOBCQL BIO-300 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [2]
Crizotinib + BIO-300 DCFW6RK BIO-300 Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + BIO-300 DCJIKAE BIO-300 Lung adenocarcinoma (Cell Line: EKVX) [2]
Crizotinib + BIO-300 DCS7K8T BIO-300 Lung adenocarcinoma (Cell Line: MDA-MB-231) [2]
Crizotinib + BIO-300 DC61VKX BIO-300 Lung adenocarcinoma (Cell Line: NCI-H522) [2]
Crizotinib + BIO-300 DCWOHO3 BIO-300 Malignant melanoma (Cell Line: LOX IMVI) [2]
Crizotinib + BIO-300 DCW86UA BIO-300 Malignant melanoma (Cell Line: UACC62) [2]
Crizotinib + BIO-300 DCOL6WJ BIO-300 Melanoma (Cell Line: MALME-3M) [2]
Crizotinib + BIO-300 DCKYTNG BIO-300 Melanoma (Cell Line: SK-MEL-2) [2]
Crizotinib + BIO-300 DCMDCNI BIO-300 Melanoma (Cell Line: UACC-257) [2]
Crizotinib + BIO-300 DC19Y83 BIO-300 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [2]
Crizotinib + BIO-300 DC1U9IE BIO-300 Non-small cell lung carcinoma (Cell Line: HOP-92) [2]
Crizotinib + BIO-300 DCPXHPK BIO-300 Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Crizotinib + BIO-300 DCXJ0T3 BIO-300 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [2]
Crizotinib + BIO-300 DCUAY16 BIO-300 Prostate carcinoma (Cell Line: PC-3) [2]
Crizotinib + BIO-300 DCX4C3V BIO-300 Renal cell carcinoma (Cell Line: UO-31) [2]
Crizotinib + BIO-300 DCOT1MY BIO-300 Renal cell carcinoma (Cell Line: SN12C) [2]
Crizotinib + Altretamine DC8KMQM Altretamine Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Altretamine DC6NQLM Altretamine Renal cell carcinoma (Cell Line: SN12C) [2]
Crizotinib + TEM DC1PA03 TEM Amelanotic melanoma (Cell Line: M14) [2]
Crizotinib + TEM DCV9WVR TEM Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Crizotinib + TEM DCJV3LJ TEM Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + TEM DCICXS9 TEM Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Crizotinib + TEM DCVH95L TEM High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Crizotinib + TEM DC9HA8T TEM Lung adenocarcinoma (Cell Line: HOP-62) [2]
Crizotinib + TEM DCOV9FQ TEM Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + JNK-IN-8 DCD1KGQ JNK-IN-8 Adenocarcinoma (Cell Line: HCT-15) [2]
Crizotinib + JNK-IN-8 DCVIJOD JNK-IN-8 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + JNK-IN-8 DCBW9HN JNK-IN-8 Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + JNK-IN-8 DC9YEW4 JNK-IN-8 Glioma (Cell Line: SF-539) [2]
Crizotinib + JNK-IN-8 DC51L0G JNK-IN-8 Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + JNK-IN-8 DCIRVHW JNK-IN-8 Malignant melanoma (Cell Line: LOX IMVI) [2]
Crizotinib + JNK-IN-8 DCU5BCZ JNK-IN-8 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Crizotinib + JNK-IN-8 DCIMIR4 JNK-IN-8 Renal cell carcinoma (Cell Line: SN12C) [2]
Crizotinib + Idarubicin DCMVTQY Idarubicin Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Idarubicin DC58TE8 Idarubicin Glioblastoma? (Cell Line: T98G) [2]
Crizotinib + Indazole derivative 5 DCRZEHA Indazole derivative 5 Adenocarcinoma (Cell Line: DU-145) [2]
Crizotinib + Indazole derivative 5 DCI1DC0 Indazole derivative 5 Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Indazole derivative 5 DC38WSQ Indazole derivative 5 Adenocarcinoma (Cell Line: HCT-15) [2]
Crizotinib + Indazole derivative 5 DCHL35T Indazole derivative 5 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Indazole derivative 5 DC4IAA4 Indazole derivative 5 Amelanotic melanoma (Cell Line: M14) [2]
Crizotinib + Indazole derivative 5 DCOOUNV Indazole derivative 5 Astrocytoma (Cell Line: U251) [2]
Crizotinib + Indazole derivative 5 DCG74HT Indazole derivative 5 Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Crizotinib + Indazole derivative 5 DCAX511 Indazole derivative 5 Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + Indazole derivative 5 DCXA1S9 Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Indazole derivative 5 DCZ8P08 Indazole derivative 5 Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Crizotinib + Indazole derivative 5 DCPTET9 Indazole derivative 5 Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + Indazole derivative 5 DCM5C8A Indazole derivative 5 Glioma (Cell Line: SF-268) [2]
Crizotinib + Indazole derivative 5 DCWX1VA Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [2]
Crizotinib + Indazole derivative 5 DCL7C5U Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Crizotinib + Indazole derivative 5 DC6B7XD Indazole derivative 5 Lung adenocarcinoma (Cell Line: HOP-62) [2]
Crizotinib + Indazole derivative 5 DCZXKE7 Indazole derivative 5 Malignant melanoma (Cell Line: UACC62) [2]
Crizotinib + Indazole derivative 5 DCJZ0NI Indazole derivative 5 Melanoma (Cell Line: SK-MEL-2) [2]
Crizotinib + Indazole derivative 5 DCOEOG0 Indazole derivative 5 Melanoma (Cell Line: UACC-257) [2]
Crizotinib + Indazole derivative 5 DCAAASU Indazole derivative 5 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Crizotinib + Indazole derivative 5 DC4S565 Indazole derivative 5 Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Imatinib DCOSU67 Imatinib Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Imatinib DC2M3GQ Imatinib Astrocytoma (Cell Line: U251) [2]
Crizotinib + Imatinib DCYLG08 Imatinib Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + Imatinib DCCA60I Imatinib Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Imatinib DCMAGFQ Imatinib Melanoma (Cell Line: UACC-257) [2]
Crizotinib + Bleomycin DCZRXRM Bleomycin Adenocarcinoma (Cell Line: A549) [2]
Crizotinib + Bleomycin DCDZQ3N Bleomycin Adenocarcinoma (Cell Line: HCC-2998) [2]
Crizotinib + Bleomycin DC8WSBE Bleomycin Adenocarcinoma (Cell Line: HCT-15) [2]
Crizotinib + Bleomycin DCVVSUJ Bleomycin Adenocarcinoma (Cell Line: SW-620) [2]
Crizotinib + Bleomycin DC45ZL8 Bleomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Crizotinib + Bleomycin DCVSX93 Bleomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Bleomycin DCBFKYY Bleomycin Astrocytoma (Cell Line: SNB-19) [2]
Crizotinib + Bleomycin DCXU7ZS Bleomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Bleomycin DCIOMT4 Bleomycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Crizotinib + Bleomycin DCGE3UK Bleomycin Glioblastoma (Cell Line: SNB-75) [2]
Crizotinib + Bleomycin DCRZPQH Bleomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Crizotinib + Bleomycin DCJJN7B Bleomycin Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Bleomycin DC7RRFS Bleomycin Lung adenocarcinoma (Cell Line: EKVX) [2]
Crizotinib + Bleomycin DC5FAQJ Bleomycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [2]
Crizotinib + Bleomycin DCMHFVX Bleomycin Malignant melanoma (Cell Line: LOX IMVI) [2]
Crizotinib + Bleomycin DCL03YS Bleomycin Melanoma (Cell Line: SK-MEL-2) [2]
Crizotinib + Bleomycin DC2W1U9 Bleomycin Renal cell carcinoma (Cell Line: SN12C) [2]
Crizotinib + Bortezomib DCFSMJE Bortezomib Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Bortezomib DCVHQHI Bortezomib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Bortezomib DC016ZH Bortezomib Amelanotic melanoma (Cell Line: M14) [2]
Crizotinib + Bortezomib DCRWWH2 Bortezomib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Crizotinib + Bortezomib DC0UFUZ Bortezomib Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + Bortezomib DCLMATY Bortezomib Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Anastrozole DC70EOU Anastrozole Adenocarcinoma (Cell Line: DU-145) [2]
Crizotinib + Anastrozole DC9P94G Anastrozole Adenocarcinoma (Cell Line: HCT-15) [2]
Crizotinib + Anastrozole DC7NGLJ Anastrozole Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Anastrozole DC7XM1F Anastrozole Amelanotic melanoma (Cell Line: M14) [2]
Crizotinib + Anastrozole DCOQN9P Anastrozole Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + Anastrozole DC8Y4HY Anastrozole Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + Anastrozole DCM9KEF Anastrozole High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Crizotinib + Anastrozole DCG3FXC Anastrozole Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Anastrozole DC3HEKF Anastrozole Lung adenocarcinoma (Cell Line: HOP-62) [2]
Crizotinib + Anastrozole DCGD65T Anastrozole Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Crizotinib + Anastrozole DCX70FT Anastrozole Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Crizotinib + Anastrozole DC8ZGFV Anastrozole Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [2]
Crizotinib + Anastrozole DCY9LYC Anastrozole Prostate carcinoma (Cell Line: PC-3) [2]
Crizotinib + Anastrozole DC6R58Y Anastrozole Renal cell carcinoma (Cell Line: UO-31) [2]
Crizotinib + Anastrozole DCN38FX Anastrozole Renal cell carcinoma (Cell Line: SN12C) [2]
Crizotinib + Dacarbazine DCL9M7T Dacarbazine Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Dacarbazine DCX5802 Dacarbazine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Dacarbazine DCG1NJN Dacarbazine Amelanotic melanoma (Cell Line: M14) [2]
Crizotinib + Dacarbazine DCB5I5M Dacarbazine Astrocytoma (Cell Line: SNB-19) [2]
Crizotinib + Dacarbazine DCN4T17 Dacarbazine Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Dacarbazine DCH592U Dacarbazine Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Crizotinib + Dacarbazine DCWVU4H Dacarbazine Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + Dacarbazine DCUVBNZ Dacarbazine Glioma (Cell Line: SF-295) [2]
Crizotinib + Dacarbazine DCG31HD Dacarbazine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Crizotinib + Dacarbazine DCL1Y10 Dacarbazine Lung adenocarcinoma (Cell Line: HOP-62) [2]
Crizotinib + Dacarbazine DCNAPSN Dacarbazine Lung adenocarcinoma (Cell Line: NCI-H522) [2]
Crizotinib + Dacarbazine DC5MSU4 Dacarbazine Melanoma (Cell Line: UACC-257) [2]
Crizotinib + Dacarbazine DCHQDY7 Dacarbazine Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Crizotinib + Dacarbazine DCH4C6T Dacarbazine Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Valrubicin DC20SCT Valrubicin Adenocarcinoma (Cell Line: DU-145) [2]
Crizotinib + Valrubicin DC8IXZO Valrubicin Adenocarcinoma (Cell Line: HCT116) [2]
Crizotinib + Valrubicin DC666Q7 Valrubicin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Crizotinib + Valrubicin DC6PW5E Valrubicin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Crizotinib + Valrubicin DC9BP4U Valrubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Crizotinib + Valrubicin DCAD8EQ Valrubicin Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Valrubicin DCJDSW2 Valrubicin Lung adenocarcinoma (Cell Line: HOP-62) [2]
Crizotinib + Valrubicin DCVHG1F Valrubicin Melanoma (Cell Line: SK-MEL-2) [2]
Crizotinib + Valrubicin DCG86DP Valrubicin Melanoma (Cell Line: MALME-3M) [2]
Crizotinib + Valrubicin DC7S6FN Valrubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Crizotinib + Valrubicin DC6440O Valrubicin Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Topotecan DCRA2OR Topotecan Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Topotecan DC2POKS Topotecan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Topotecan DCR24DS Topotecan Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
Crizotinib + Topotecan DCCXT05 Topotecan Astrocytoma (Cell Line: SNB-19) [2]
Crizotinib + Topotecan DCL15VD Topotecan Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Crizotinib + Topotecan DCWX62J Topotecan Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Crizotinib + Topotecan DCJJVPF Topotecan Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + Topotecan DCM7AAA Topotecan Glioma (Cell Line: SF-268) [2]
Crizotinib + Topotecan DC4XODQ Topotecan High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [2]
Crizotinib + Topotecan DCY52EB Topotecan High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Crizotinib + Topotecan DCFSMXP Topotecan Melanoma (Cell Line: MALME-3M) [2]
Crizotinib + Topotecan DCMA5T6 Topotecan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Crizotinib + Topotecan DCLUWW3 Topotecan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [2]
Crizotinib + Topotecan DCZASUN Topotecan Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [2]
Crizotinib + Topotecan DCM1X4G Topotecan Prostate carcinoma (Cell Line: PC-3) [2]
Crizotinib + Topotecan DCDHFXM Topotecan Renal cell carcinoma (Cell Line: UO-31) [2]
Crizotinib + Cabazitaxel DCX7HHI Cabazitaxel Adenocarcinoma (Cell Line: DU-145) [2]
Crizotinib + Cabazitaxel DC82TQR Cabazitaxel Adenocarcinoma (Cell Line: A549) [2]
Crizotinib + Cabazitaxel DCGSJMY Cabazitaxel Adenocarcinoma (Cell Line: NCIH23) [2]
Crizotinib + Cabazitaxel DC9KU1R Cabazitaxel Adenocarcinoma (Cell Line: SW-620) [2]
Crizotinib + Cabazitaxel DC4JDXB Cabazitaxel Adenocarcinoma (Cell Line: HT29) [2]
Crizotinib + Cabazitaxel DCWNGYZ Cabazitaxel Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Crizotinib + Cabazitaxel DCH7H9H Cabazitaxel Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
Crizotinib + Cabazitaxel DCCZM0M Cabazitaxel Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + Cabazitaxel DCW68QN Cabazitaxel Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + Cabazitaxel DC36T66 Cabazitaxel Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Crizotinib + Cabazitaxel DCLC0XH Cabazitaxel Glioma (Cell Line: SF-268) [2]
Crizotinib + Cabazitaxel DC2RYQZ Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Crizotinib + Cabazitaxel DC22VFY Cabazitaxel Lung adenocarcinoma (Cell Line: EKVX) [2]
Crizotinib + Cabazitaxel DCY5JF7 Cabazitaxel Malignant melanoma (Cell Line: UACC62) [2]
Crizotinib + Cabazitaxel DCMHBPN Cabazitaxel Melanoma (Cell Line: MALME-3M) [2]
Crizotinib + Cabazitaxel DCJ7X3G Cabazitaxel Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [2]
Crizotinib + Cabazitaxel DCQ764G Cabazitaxel Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Crizotinib + Cabazitaxel DC3CFH8 Cabazitaxel Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [2]
Crizotinib + Epirubicin DCPCONN Epirubicin Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Epirubicin DC6WDN7 Epirubicin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Epirubicin DC8LF53 Epirubicin Amelanotic melanoma (Cell Line: M14) [2]
Crizotinib + Epirubicin DCFSTQV Epirubicin Astrocytoma (Cell Line: U251) [2]
Crizotinib + Epirubicin DCD527H Epirubicin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Crizotinib + Epirubicin DCIUO2Y Epirubicin Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Crizotinib + Epirubicin DC60HAJ Epirubicin Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + Epirubicin DCRSUTD Epirubicin Glioma (Cell Line: SF-539) [2]
Crizotinib + Epirubicin DC4IQB6 Epirubicin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Crizotinib + Epirubicin DC4ZNSR Epirubicin Lung adenocarcinoma (Cell Line: HOP-62) [2]
Crizotinib + Epirubicin DCXIWF3 Epirubicin Malignant melanoma (Cell Line: LOX IMVI) [2]
Crizotinib + Epirubicin DC84ONC Epirubicin Melanoma (Cell Line: UACC-257) [2]
Crizotinib + Epirubicin DCTW6ZC Epirubicin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Crizotinib + Epirubicin DC488S2 Epirubicin Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Crizotinib + Epirubicin DCO05AN Epirubicin Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Cisplatin DCS7LCF Cisplatin Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Vandetanib DCB2ZQQ Vandetanib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Vandetanib DCQXPIB Vandetanib Astrocytoma (Cell Line: U251) [2]
Crizotinib + Vandetanib DCSSBOF Vandetanib Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Chlorambucil DC3JXB2 Chlorambucil Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Chlorambucil DCUUUQB Chlorambucil Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + Chlorambucil DCPBKL9 Chlorambucil Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Sorafenib DCXOUAS Sorafenib Astrocytoma (Cell Line: U251) [2]
Crizotinib + Sorafenib DCYCGZ4 Sorafenib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Crizotinib + ER819762 DCLMFB2 ER819762 Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + ER819762 DCK0PBD ER819762 Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + PF-562271 DCU6XJM PF-562271 Diffuse large B cell lymphoma (Cell Line: TMD8) [2]
Crizotinib + Romidepsin DCUD41N Romidepsin Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + Romidepsin DCG82BY Romidepsin Lung adenocarcinoma (Cell Line: EKVX) [2]
Crizotinib + Romidepsin DCQN3JE Romidepsin Lung adenocarcinoma (Cell Line: NCI-H522) [2]
Crizotinib + Romidepsin DCI75I1 Romidepsin Renal cell carcinoma (Cell Line: UO-31) [2]
Crizotinib + Azacitidine DCUMX1B Azacitidine Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + Azacitidine DCXUT6W Azacitidine Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Crizotinib + Azacitidine DCXPVDA Azacitidine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [2]
Crizotinib + Pomalidomide DCX1HI0 Pomalidomide Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Pomalidomide DCFIW61 Pomalidomide Amelanotic melanoma (Cell Line: M14) [2]
Crizotinib + Pomalidomide DCDWVUY Pomalidomide Astrocytoma (Cell Line: U251) [2]
Crizotinib + Pomalidomide DC2EYVP Pomalidomide Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Pomalidomide DC2JNDW Pomalidomide Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Crizotinib + Pomalidomide DC2PKYK Pomalidomide Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + Pomalidomide DCVNSKS Pomalidomide Glioma (Cell Line: SF-539) [2]
Crizotinib + Pomalidomide DC4XJKH Pomalidomide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [2]
Crizotinib + Pomalidomide DC278MO Pomalidomide High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Crizotinib + Pomalidomide DC8GE8W Pomalidomide Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Crizotinib + Pomalidomide DCEXUHS Pomalidomide Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Pomalidomide DCRH4ZC Pomalidomide Renal cell carcinoma (Cell Line: UO-31) [2]
Crizotinib + Vinflunine DCNBGRL Vinflunine Adenocarcinoma (Cell Line: NCIH23) [2]
Crizotinib + Vinflunine DCCMSOQ Vinflunine Adenocarcinoma (Cell Line: HCT-15) [2]
Crizotinib + Vinflunine DC8UAYU Vinflunine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Vinflunine DC98O7V Vinflunine Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
Crizotinib + Vinflunine DCUVA90 Vinflunine Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + Vinflunine DCEKX6D Vinflunine Clear cell renal cell carcinoma (Cell Line: A498) [2]
Crizotinib + Vinflunine DC6302U Vinflunine Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Crizotinib + Vinflunine DCSNX5H Vinflunine Glioma (Cell Line: SF-295) [2]
Crizotinib + Vinflunine DCXXTJG Vinflunine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [2]
Crizotinib + Vinflunine DCYVNOM Vinflunine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Crizotinib + Vinflunine DCKVOKI Vinflunine Renal cell carcinoma (Cell Line: SN12C) [2]
Crizotinib + Taxol DCI36BQ Taxol Adenocarcinoma (Cell Line: HT29) [2]
Crizotinib + Taxol DC4MCSE Taxol Adenocarcinoma (Cell Line: HCT-15) [2]
Crizotinib + Taxol DC7B59L Taxol Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Crizotinib + Taxol DC7Y8TD Taxol Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Taxol DCRBMUZ Taxol Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + Taxol DCBTU2H Taxol Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Crizotinib + Taxol DC1XZQ3 Taxol Lung adenocarcinoma (Cell Line: MDA-MB-231) [2]
Crizotinib + Taxol DCQ2AER Taxol Malignant melanoma (Cell Line: LOX IMVI) [2]
Crizotinib + Taxol DCSEUSO Taxol Malignant melanoma (Cell Line: UACC62) [2]
Crizotinib + Taxol DCT6P38 Taxol Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [2]
Crizotinib + Fludarabine DC86RAC Fludarabine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Crizotinib + Fludarabine DCBA85U Fludarabine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [2]
Crizotinib + Fludarabine DCUZQFH Fludarabine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Crizotinib + Fludarabine DC7H8O2 Fludarabine Renal cell carcinoma (Cell Line: UO-31) [2]
Crizotinib + Fludarabine DCP7GDQ Fludarabine Renal cell carcinoma (Cell Line: SN12C) [2]
Crizotinib + PMID28870136-Compound-43 DC4IMKZ PMID28870136-Compound-43 Amelanotic melanoma (Cell Line: M14) [2]
Crizotinib + PMID28870136-Compound-43 DCU2ZIW PMID28870136-Compound-43 Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + PMID28870136-Compound-43 DCX862G PMID28870136-Compound-43 Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + PMID28870136-Compound-43 DCACNSB PMID28870136-Compound-43 Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + PMID28870136-Compound-43 DC1D8KQ PMID28870136-Compound-43 High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Crizotinib + PMID28870136-Compound-43 DC93SU9 PMID28870136-Compound-43 Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + FORMESTANE DCKC7ZO FORMESTANE Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + FORMESTANE DC8T8MD FORMESTANE Adenocarcinoma (Cell Line: HCT-15) [2]
Crizotinib + FORMESTANE DCNCQSX FORMESTANE Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Crizotinib + FORMESTANE DCMD84O FORMESTANE Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + FORMESTANE DCWDIPB FORMESTANE Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + FORMESTANE DCC8LTI FORMESTANE Melanoma (Cell Line: UACC-257) [2]
Crizotinib + FORMESTANE DCR9SF4 FORMESTANE Non-small cell lung carcinoma (Cell Line: HOP-92) [2]
Crizotinib + Aminolevulinic Acid Hydrochloride DC22C4K Aminolevulinic Acid Hydrochloride Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Crizotinib + Estramustine DCWVZFS Estramustine Adenocarcinoma (Cell Line: DU-145) [2]
Crizotinib + Estramustine DCVRCDB Estramustine Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Estramustine DCLLBME Estramustine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Crizotinib + Estramustine DC1T9Y9 Estramustine Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + Estramustine DC72APL Estramustine Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Estramustine DCGHMIR Estramustine Glioma (Cell Line: SF-268) [2]
Crizotinib + Estramustine DCRFUBG Estramustine Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Digitoxin DC2B108 Digitoxin Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + Digitoxin DCBLO11 Digitoxin Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Crizotinib + Digitoxin DC654JN Digitoxin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [2]
Crizotinib + Digitoxin DC1V09B Digitoxin Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Digitoxin DCYAASH Digitoxin Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Dasatinib DC7CM9K Dasatinib Adenocarcinoma (Cell Line: DU-145) [2]
Crizotinib + Dasatinib DC8GWRW Dasatinib Adenocarcinoma (Cell Line: A549) [2]
Crizotinib + Dasatinib DC74W5D Dasatinib Adenocarcinoma (Cell Line: HT29) [2]
Crizotinib + Dasatinib DCCILNB Dasatinib Astrocytoma (Cell Line: U251) [2]
Crizotinib + Dasatinib DCEHK4S Dasatinib Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + Dasatinib DC84GSH Dasatinib Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Crizotinib + Dasatinib DCRUZA9 Dasatinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Crizotinib + Dasatinib DC43WUP Dasatinib Glioma (Cell Line: SF-268) [2]
Crizotinib + Dasatinib DCUR88V Dasatinib Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Dasatinib DC7ZT0X Dasatinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [2]
Crizotinib + Dasatinib DCMZ3OV Dasatinib Lung adenocarcinoma (Cell Line: EKVX) [2]
Crizotinib + Dasatinib DCWFOK7 Dasatinib Lung adenocarcinoma (Cell Line: HOP-62) [2]
Crizotinib + Dasatinib DCYXX70 Dasatinib Lung adenocarcinoma (Cell Line: NCI-H522) [2]
Crizotinib + Dasatinib DC8TRHK Dasatinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Crizotinib + Dasatinib DCJ4FZG Dasatinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [2]
Crizotinib + Dasatinib DCY4KUE Dasatinib Non-small cell lung carcinoma (Cell Line: HOP-92) [2]
Crizotinib + Dasatinib DCV3QWN Dasatinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Crizotinib + Dasatinib DC3H4CV Dasatinib Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Crizotinib + Dasatinib DCP4R8G Dasatinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [2]
Crizotinib + Dasatinib DCDG694 Dasatinib Prostate carcinoma (Cell Line: PC-3) [2]
Crizotinib + Mechlorethamine DCGUPUO Mechlorethamine Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Pentostatin DCH79MW Pentostatin Invasive ductal carcinoma (Cell Line: BT-549) [3]
Crizotinib + Pentostatin DCUX2D5 Pentostatin Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Pentostatin DCNGZL8 Pentostatin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + Picoplatin DCZWVLT Picoplatin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + Picoplatin DCTOLBG Picoplatin Carcinoma (Cell Line: RXF 393) [3]
Crizotinib + Picoplatin DCSF0KH Picoplatin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + Fulvestrant DC3OYU6 Fulvestrant Carcinoma (Cell Line: MCF7) [3]
Crizotinib + Fulvestrant DCFEHTU Fulvestrant Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + Fulvestrant DCRWNED Fulvestrant Invasive ductal carcinoma (Cell Line: BT-549) [3]
Crizotinib + Gefitinib DCVJKJH Gefitinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + Gefitinib DCJ38L2 Gefitinib Colon carcinoma (Cell Line: KM12) [3]
Crizotinib + Gefitinib DCI2CTG Gefitinib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Gefitinib DCIAGZG Gefitinib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + Ruxolitinib DC8X7JH Ruxolitinib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Hepzato DC2GJWD Hepzato Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Hepzato DC9HQAY Hepzato Invasive ductal carcinoma (Cell Line: BT-549) [3]
Crizotinib + Hepzato DCLVNQV Hepzato Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + Ixabepilone DCGEGDT Ixabepilone Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + Ixabepilone DCK8KWX Ixabepilone Carcinoma (Cell Line: MCF7) [3]
Crizotinib + Ixabepilone DCU7UID Ixabepilone Colon carcinoma (Cell Line: KM12) [3]
Crizotinib + Ixabepilone DCRQ15A Ixabepilone Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Dactinomycin DCAWYGN Dactinomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + Dactinomycin DC2UWOA Dactinomycin Carcinoma (Cell Line: RXF 393) [3]
Crizotinib + Dactinomycin DCSUD37 Dactinomycin Carcinoma (Cell Line: MCF7) [3]
Crizotinib + Dactinomycin DCEHYNT Dactinomycin Colon adenocarcinoma (Cell Line: COLO 205) [3]
Crizotinib + Dactinomycin DCHIZD5 Dactinomycin Colon carcinoma (Cell Line: KM12) [3]
Crizotinib + Dactinomycin DCM6MKZ Dactinomycin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + Dactinomycin DCQWVQ7 Dactinomycin Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Dactinomycin DCPJVP9 Dactinomycin Invasive ductal carcinoma (Cell Line: BT-549) [3]
Crizotinib + DFN-15 DC3IJWX DFN-15 Invasive ductal carcinoma (Cell Line: BT-549) [3]
Crizotinib + DFN-15 DCM0W6A DFN-15 Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + Lapatinib DCV0NB6 Lapatinib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + PMID28460551-Compound-2 DCUWTQM PMID28460551-Compound-2 Carcinoma (Cell Line: RXF 393) [3]
Crizotinib + Cyclophosphamide DCFU2H6 Cyclophosphamide Carcinoma (Cell Line: RXF 393) [3]
Crizotinib + Isoniazid DC72ID3 Isoniazid Invasive ductal carcinoma (Cell Line: BT-549) [3]
Crizotinib + Vemurafenib DCDAYMD Vemurafenib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Lenalidomide DCLN28A Lenalidomide Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + Lenalidomide DC8RZBD Lenalidomide Invasive ductal carcinoma (Cell Line: BT-549) [3]
Crizotinib + Plicamycin DCNAOT2 Plicamycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + Plicamycin DC8E6GH Plicamycin Carcinoma (Cell Line: RXF 393) [3]
Crizotinib + Plicamycin DCIGX4H Plicamycin Carcinoma (Cell Line: MCF7) [3]
Crizotinib + Plicamycin DCZ73OY Plicamycin Colon adenocarcinoma (Cell Line: COLO 205) [3]
Crizotinib + Plicamycin DCVCNVM Plicamycin Colon carcinoma (Cell Line: KM12) [3]
Crizotinib + Plicamycin DCQ3VUC Plicamycin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + Plicamycin DCTE2BZ Plicamycin Invasive ductal carcinoma (Cell Line: BT-549) [3]
Crizotinib + Plicamycin DCBOZI7 Plicamycin Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Nilotinib DC4MB5O Nilotinib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Nilotinib DCCS4AU Nilotinib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + Thioguanine DCXGVBM Thioguanine Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + Thioguanine DC1IBTV Thioguanine Carcinoma (Cell Line: MCF7) [3]
Crizotinib + Thioguanine DC9VSKD Thioguanine Colon adenocarcinoma (Cell Line: COLO 205) [3]
Crizotinib + Thioguanine DCFZXYY Thioguanine Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + ABIRATERONE DCJLE5H ABIRATERONE Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + ABIRATERONE DCYD2VV ABIRATERONE Invasive ductal carcinoma (Cell Line: BT-549) [3]
Crizotinib + 10-hydroxycamptothecin DCTT6ZN 10-hydroxycamptothecin Colon adenocarcinoma (Cell Line: COLO 205) [3]
Crizotinib + Amonafide DCTOCWO Amonafide Colon carcinoma (Cell Line: KM12) [3]
Crizotinib + Pralatrexate DCPLQIF Pralatrexate Colon carcinoma (Cell Line: KM12) [3]
Crizotinib + Pralatrexate DC48BWR Pralatrexate Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Terameprocol DCN5UNA Terameprocol Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + Terameprocol DC8ZOGD Terameprocol Carcinoma (Cell Line: RXF 393) [3]
Crizotinib + Terameprocol DC9MNOY Terameprocol Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Terameprocol DCPOP0B Terameprocol Invasive ductal carcinoma (Cell Line: BT-549) [3]
Crizotinib + Terameprocol DC9V8B5 Terameprocol Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + SCH 727965 DCUBI3M SCH 727965 Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + SCH 727965 DCGLOIU SCH 727965 Carcinoma (Cell Line: RXF 393) [3]
Crizotinib + SCH 727965 DCOVHDZ SCH 727965 Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + SCH 727965 DCKG25Q SCH 727965 Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Ifosfamide DCDE5KD Ifosfamide Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Dexrazoxane DC1HAKJ Dexrazoxane Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + Dexrazoxane DCRHH5M Dexrazoxane Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Docetaxel DC4SAXT Docetaxel Colon adenocarcinoma (Cell Line: COLO 205) [3]
Crizotinib + Raloxifene DCX7FWZ Raloxifene Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + Raloxifene DCSQG1M Raloxifene Carcinoma (Cell Line: MCF7) [3]
Crizotinib + Raloxifene DCZROHI Raloxifene Invasive ductal carcinoma (Cell Line: BT-549) [3]
Crizotinib + Raloxifene DCOBTPY Raloxifene Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Raloxifene DCQUF1J Raloxifene Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + Bendamustine hydrochloride DC1MKAU Bendamustine hydrochloride Carcinoma (Cell Line: RXF 393) [3]
Crizotinib + Bendamustine hydrochloride DC4ZWDW Bendamustine hydrochloride Carcinoma (Cell Line: MCF7) [3]
Crizotinib + Bendamustine hydrochloride DCTBIRV Bendamustine hydrochloride Colon carcinoma (Cell Line: KM12) [3]
Crizotinib + Bendamustine hydrochloride DC7AFEA Bendamustine hydrochloride Invasive ductal carcinoma (Cell Line: BT-549) [3]
Crizotinib + Trifluridine DCV8JU2 Trifluridine Invasive ductal carcinoma (Cell Line: BT-549) [3]
Crizotinib + Sirolimus DCFMS3T Sirolimus Carcinoma (Cell Line: MCF7) [3]
Crizotinib + Sirolimus DCNNGD5 Sirolimus Colon carcinoma (Cell Line: KM12) [3]
Crizotinib + Letrozole DCXI7U0 Letrozole Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + Letrozole DCPLZTF Letrozole Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + Letrozole DCOUO00 Letrozole Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Letrozole DC6ETZH Letrozole Invasive ductal carcinoma (Cell Line: BT-549) [3]
Crizotinib + Mitomycin DC0TRBA Mitomycin Carcinoma (Cell Line: RXF 393) [3]
Crizotinib + Mitomycin DCWS2KT Mitomycin Carcinoma (Cell Line: MCF7) [3]
Crizotinib + Mitomycin DC2ZPBJ Mitomycin Invasive ductal carcinoma (Cell Line: BT-549) [3]
Crizotinib + Mitomycin DC312QD Mitomycin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + Uracil mustard DCHXK0H Uracil mustard Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + Uracil mustard DCJIR7Y Uracil mustard Colon carcinoma (Cell Line: KM12) [3]
Crizotinib + Arfolitixorin DCX3G02 Arfolitixorin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + BIO-300 DCGKMDU BIO-300 Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + BIO-300 DCFUS34 BIO-300 Carcinoma (Cell Line: MCF7) [3]
Crizotinib + BIO-300 DC8XAKX BIO-300 Colon adenocarcinoma (Cell Line: COLO 205) [3]
Crizotinib + BIO-300 DCXMRUH BIO-300 Colon carcinoma (Cell Line: KM12) [3]
Crizotinib + Altretamine DCSQTGE Altretamine Carcinoma (Cell Line: RXF 393) [3]
Crizotinib + TEM DCXDRCC TEM Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + TEM DC5URN2 TEM Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + TEM DCNXLFV TEM Invasive ductal carcinoma (Cell Line: BT-549) [3]
Crizotinib + JNK-IN-8 DCH7QAO JNK-IN-8 Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + JNK-IN-8 DC7RM1Y JNK-IN-8 Colon carcinoma (Cell Line: KM12) [3]
Crizotinib + Indazole derivative 5 DC4MJ7Z Indazole derivative 5 Colon carcinoma (Cell Line: KM12) [3]
Crizotinib + Indazole derivative 5 DCAN6F2 Indazole derivative 5 Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + Indazole derivative 5 DCFN9CO Indazole derivative 5 Invasive ductal carcinoma (Cell Line: BT-549) [3]
Crizotinib + Indazole derivative 5 DCOVV23 Indazole derivative 5 Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Imatinib DCK6T8D Imatinib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Bleomycin DCNE0AS Bleomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + Bleomycin DC81YIX Bleomycin Colon carcinoma (Cell Line: KM12) [3]
Crizotinib + Bortezomib DC1H8MO Bortezomib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Bortezomib DCERUMO Bortezomib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + Anastrozole DCBTJIR Anastrozole Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + Anastrozole DCMHV8H Anastrozole Colon carcinoma (Cell Line: KM12) [3]
Crizotinib + Anastrozole DC60WHV Anastrozole Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + Dacarbazine DCYVJ32 Dacarbazine Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + Dacarbazine DCMJPZU Dacarbazine Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + Dacarbazine DC6H27Q Dacarbazine Invasive ductal carcinoma (Cell Line: BT-549) [3]
Crizotinib + Dacarbazine DCFTGI3 Dacarbazine Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Valrubicin DCGPB5U Valrubicin Carcinoma (Cell Line: MCF7) [3]
Crizotinib + Topotecan DCRK8ZG Topotecan Carcinoma (Cell Line: MCF7) [3]
Crizotinib + Topotecan DCHOKHK Topotecan Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + Cabazitaxel DCLCKMS Cabazitaxel Colon adenocarcinoma (Cell Line: COLO 205) [3]
Crizotinib + Epirubicin DCBFSJ0 Epirubicin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + Epirubicin DC3XL78 Epirubicin Invasive ductal carcinoma (Cell Line: BT-549) [3]
Crizotinib + Epirubicin DCADJTY Epirubicin Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Epirubicin DCJUULH Epirubicin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + Cisplatin DC8G4T9 Cisplatin Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Vandetanib DC34IJY Vandetanib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Crizotinib + Chlorambucil DCC7UAK Chlorambucil Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Azacitidine DCK2DQD Azacitidine Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Pomalidomide DCQN194 Pomalidomide Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Pomalidomide DC7M9RZ Pomalidomide Invasive ductal carcinoma (Cell Line: BT-549) [3]
Crizotinib + Vinflunine DCNPCUH Vinflunine Carcinoma (Cell Line: MCF7) [3]
Crizotinib + Vinflunine DCZG66G Vinflunine Colon carcinoma (Cell Line: KM12) [3]
Crizotinib + Fludarabine DCTMN14 Fludarabine Colon carcinoma (Cell Line: KM12) [3]
Crizotinib + PMID28870136-Compound-43 DCUOSAK PMID28870136-Compound-43 Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + FORMESTANE DCMYPYZ FORMESTANE Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Estramustine DC6KJ1I Estramustine Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + Estramustine DC9ONZ0 Estramustine Carcinoma (Cell Line: RXF 393) [3]
Crizotinib + Estramustine DC0LK47 Estramustine Carcinoma (Cell Line: MCF7) [3]
Crizotinib + Estramustine DCITY2M Estramustine Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Dasatinib DCN96HJ Dasatinib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Dacarbazine + Crizotinib DCVBZUV Dacarbazine Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Dacarbazine + Crizotinib DC5HKLR Dacarbazine Glioma (Cell Line: SF-295) [2]
Dacarbazine + Crizotinib DCXE32D Dacarbazine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Dacarbazine + Crizotinib DCRGP0C Dacarbazine Lung adenocarcinoma (Cell Line: HOP-62) [2]
Dacarbazine + Crizotinib DCD171U Dacarbazine Malignant melanoma (Cell Line: LOX IMVI) [2]
Dacarbazine + Crizotinib DCHVUDA Dacarbazine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Dacarbazine + Crizotinib DC1301X Dacarbazine Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Dacarbazine + Crizotinib DC6YV5O Dacarbazine Renal cell carcinoma (Cell Line: SN12C) [2]
Dexrazoxane + Crizotinib DCTQVRI Dexrazoxane High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Dexrazoxane + Crizotinib DCZ6J3K Dexrazoxane Malignant melanoma (Cell Line: LOX IMVI) [4]
Dexrazoxane + Crizotinib DCZDMBG Dexrazoxane Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Epirubicin + Crizotinib DC57WDH Epirubicin Astrocytoma (Cell Line: U251) [2]
Epirubicin + Crizotinib DCEUXGM Epirubicin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Crizotinib DCY2O35 Epirubicin Glioma (Cell Line: SF-539) [2]
Epirubicin + Crizotinib DCXOM1B Epirubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Epirubicin + Crizotinib DCN744Q Epirubicin Melanoma (Cell Line: UACC-257) [4]
Erlotinib + Crizotinib DC57P2N Erlotinib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Everolimus + Crizotinib DCJE23G Everolimus Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Gefitinib + Crizotinib DC6H23R Gefitinib Adenocarcinoma (Cell Line: DU-145) [2]
Gefitinib + Crizotinib DCJ7MZE Gefitinib Amelanotic melanoma (Cell Line: M14) [2]
Gefitinib + Crizotinib DCUUSGL Gefitinib Anaplastic large cell lymphoma (Cell Line: SR) [2]
Gefitinib + Crizotinib DCN8KWT Gefitinib Lung adenocarcinoma (Cell Line: EKVX) [2]
Gefitinib + Crizotinib DCC9Y4G Gefitinib Melanoma (Cell Line: MALME-3M) [2]
Gefitinib + Crizotinib DCV47W2 Gefitinib Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Gefitinib + Crizotinib DCZDQJK Gefitinib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Indazole derivative 5 + Crizotinib DC8KNJP Indazole derivative 5 Chronic myelogenous leukemia (Cell Line: K-562) [2]
Indazole derivative 5 + Crizotinib DC99I14 Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Indazole derivative 5 + Crizotinib DCGF7OD Indazole derivative 5 Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Indazole derivative 5 + Crizotinib DC7AWS6 Indazole derivative 5 Colon carcinoma (Cell Line: KM12) [3]
Indazole derivative 5 + Crizotinib DCL67R1 Indazole derivative 5 Malignant melanoma (Cell Line: UACC62) [4]
Indazole derivative 5 + Crizotinib DCZDG5P Indazole derivative 5 Melanoma (Cell Line: UACC-257) [4]
Indazole derivative 5 + Crizotinib DC5GSAQ Indazole derivative 5 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
JNK-IN-8 + Crizotinib DC0GXCU JNK-IN-8 Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
JNK-IN-8 + Crizotinib DC8TV3I JNK-IN-8 Glioma (Cell Line: SF-295) [2]
JNK-IN-8 + Crizotinib DCPXNC8 JNK-IN-8 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Lenalidomide + Crizotinib DC99Q2F Lenalidomide Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Lenalidomide + Crizotinib DC17OSV Lenalidomide Invasive ductal carcinoma (Cell Line: HS 578T) [3]
LY2835219 + Crizotinib DCXUMGU LY2835219 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Mechlorethamine + Crizotinib DC6EF8A Mechlorethamine Glioma (Cell Line: SF-295) [2]
Mechlorethamine + Crizotinib DCREBIA Mechlorethamine Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Mechlorethamine + Crizotinib DC1GW5M Mechlorethamine Adenocarcinoma (Cell Line: OVCAR3) [4]
Mechlorethamine + Crizotinib DC27ILS Mechlorethamine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Mechlorethamine + Crizotinib DC290MY Mechlorethamine Malignant melanoma (Cell Line: LOX IMVI) [4]
Mechlorethamine + Crizotinib DC9XG16 Mechlorethamine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Picoplatin + Crizotinib DCI8WCL Picoplatin Glioma (Cell Line: SF-295) [2]
Picoplatin + Crizotinib DCLWEKW Picoplatin Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Picoplatin + Crizotinib DCSB0VS Picoplatin Invasive ductal carcinoma (Cell Line: BT-549) [3]
Picoplatin + Crizotinib DCPFGPH Picoplatin Lung adenocarcinoma (Cell Line: HOP-62) [4]
Picoplatin + Crizotinib DC0JB3A Picoplatin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Raloxifene + Crizotinib DCC42OQ Raloxifene Adenocarcinoma (Cell Line: DU-145) [4]
Ruxolitinib + Crizotinib DC36MUF Ruxolitinib Astrocytoma (Cell Line: U251) [2]
Ruxolitinib + Crizotinib DCR5S6Y Ruxolitinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Ruxolitinib + Crizotinib DCW3TCL Ruxolitinib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Ruxolitinib + Crizotinib DCG6BZ6 Ruxolitinib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Ruxolitinib + Crizotinib DCYBIBH Ruxolitinib Melanoma (Cell Line: UACC-257) [4]
Thioguanine + Crizotinib DCU1CBL Thioguanine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Thioguanine + Crizotinib DCREDHZ Thioguanine Glioma (Cell Line: SF-295) [2]
Thioguanine + Crizotinib DCDMVS7 Thioguanine Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Thioguanine + Crizotinib DCTQPN0 Thioguanine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Topotecan + Crizotinib DCP3OQ3 Topotecan Adenocarcinoma (Cell Line: A549) [4]
Topotecan + Crizotinib DCMWSRY Topotecan Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Topotecan + Crizotinib DC55KFV Topotecan Glioma (Cell Line: SF-268) [4]
Topotecan + Crizotinib DC5GNKS Topotecan Melanoma (Cell Line: MALME-3M) [4]
Topotecan + Crizotinib DCXV3S8 Topotecan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Topotecan + Crizotinib DCJERAI Topotecan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Topotecan + Crizotinib DC520G9 Topotecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Topotecan + Crizotinib DCBNEED Topotecan Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Topotecan + Crizotinib DC0YWBQ Topotecan Prostate carcinoma (Cell Line: PC-3) [4]
Topotecan + Crizotinib DCTJEDG Topotecan Renal cell carcinoma (Cell Line: SN12C) [4]
Tosyl-l-arginine methyl ester + Crizotinib DCWTLVZ Tosyl-l-arginine methyl ester Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Trifluridine + Crizotinib DC170GS Trifluridine Astrocytoma (Cell Line: SNB-19) [2]
Trifluridine + Crizotinib DCHQUAN Trifluridine Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Trifluridine + Crizotinib DCWR8TX Trifluridine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Trifluridine + Crizotinib DCV1VWJ Trifluridine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Uracil mustard + Crizotinib DC3CF5F Uracil mustard High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Vandetanib + Crizotinib DCQH26D Vandetanib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Crizotinib DCDABXL Vandetanib Adenocarcinoma (Cell Line: NCIH23) [4]
Vandetanib + Crizotinib DC0BRVR Vandetanib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Crizotinib DCP4TRJ Vandetanib Astrocytoma (Cell Line: U251) [4]
Vandetanib + Crizotinib DCSINZ8 Vandetanib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Vandetanib + Crizotinib DCW6BTG Vandetanib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vandetanib + Crizotinib DC0K812 Vandetanib Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Crizotinib DCOI8UN Vandetanib Melanoma (Cell Line: UACC-257) [4]
Vemurafenib + Crizotinib DCGLZVK Vemurafenib Astrocytoma (Cell Line: U251) [4]
Vemurafenib + Crizotinib DCWMLWL Vemurafenib Malignant melanoma (Cell Line: LOX IMVI) [4]
Vemurafenib + Crizotinib DCG5RMP Vemurafenib Melanoma (Cell Line: UACC-257) [4]
Vincristine + Crizotinib DCLBKHS Vincristine Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Vismodegib + Crizotinib DCBNAHU Vismodegib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vismodegib + Crizotinib DCGG5WM Vismodegib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vismodegib + Crizotinib DCNLFSE Vismodegib Astrocytoma (Cell Line: U251) [4]
Vismodegib + Crizotinib DCSNJEL Vismodegib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vismodegib + Crizotinib DC0JU1G Vismodegib Melanoma (Cell Line: UACC-257) [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 1013 DrugCom(s)
10 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Arry-162 + Crizotinib DC096TP Arry-162 Solid Tumor [5]
Crizotinib + Axitinib DC4BKE1 Axitinib Solid Tumors [6]
Crizotinib + Dasatinib DC6G7W1 Dasatinib Diffuse Intrinsic Pontine Glioma [7]
Crizotinib + Erlotinib DCFQJ4P Erlotinib Non-Small Cell Lung Cancer [8]
Crizotinib + Dasatinib DCMIGX4 Dasatinib Advanced Cancers [9]
Crizotinib + Pazopanib DCXW0I5 Pazopanib Advanced Cancers [10]
Crizotinib + Rifampicin DCGQSU9 Rifampicin Non-Small Cell Lung Cancer ALK-positive [11]
Crizotinib + Lorlatinib DC59Z33 Lorlatinib Lung Cancer [12]
Crizotinib + Axitinib DCOWVBN Axitinib Advanced Solid Tumors [13]
Crizotinib + Enzalutamide DCU75S9 Enzalutamide Castration-resistant Prostate Cancer [14]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DrugCom(s)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4903).
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
4 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
5 ClinicalTrials.gov (NCT02510001) MEK and MET Inhibition in Colorectal Cancer
6 ClinicalTrials.gov (NCT00828919) Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials
7 ClinicalTrials.gov (NCT01644773) Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
8 ClinicalTrials.gov (NCT00965731) Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
9 ClinicalTrials.gov (NCT01744652) Dasatinib and Crizotinib in Advanced Cancer
10 ClinicalTrials.gov (NCT01548144) Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
11 ClinicalTrials.gov (NCT00585195) A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
12 ClinicalTrials.gov (NCT04292119) Lorlatinib Combinations in Lung Cancer
13 ClinicalTrials.gov (NCT01999972) A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
14 ClinicalTrials.gov (NCT02207504) Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer